rs7101429 — GAB2 GAB2 Alzheimer's risk modifier

GAB2 — A Signal Transduction Scaffold That Modifies Alzheimer's Risk

GAB2 (GRB2-associated-binding protein 2)¹¹ GAB2 (GRB2-associated-binding protein 2)
a scaffolding adapter protein that coordinates intracellular signaling downstream of growth factor and cytokine receptors encodes a key node in the PI3K/AKT signaling cascade. In neurons, this pathway regulates the activity of GSK-3β (glycogen synthase kinase-3 beta)²² GSK-3β (glycogen synthase kinase-3 beta)
an enzyme that phosphorylates tau protein; excess tau phosphorylation leads to neurofibrillary tangles, a hallmark of Alzheimer's disease. The rs7101429 variant sits deep within an intron of GAB2 and appears to act as a regulatory tag³³ regulatory tag
an expression quantitative trait locus affecting how much GAB2 protein the neuron produces. The minor G allele at this locus is protective: carriers produce more GAB2 protein, which keeps GSK-3β in check and limits pathological tau phosphorylation.

The Mechanism

GAB2 functions by recruiting and activating PI3K after receptor stimulation, leading to AKT phosphorylation and the consequent inhibition of GSK-3β. When GSK-3β activity is suppressed, tau remains in its normal, soluble, microtubule-stabilizing form. When GAB2 expression or function is reduced — as in carriers of the common A allele — PI3K/AKT signaling is weaker, GSK-3β is less inhibited, and tau hyperphosphorylation becomes more likely.

Reiman et al. demonstrated that interfering with GAB2 expression directly increased tau phosphorylation in cell models⁴⁴ Reiman et al. demonstrated that interfering with GAB2 expression directly increased tau phosphorylation in cell models
providing the mechanistic basis for the genetic association. This biologically grounded mechanism distinguishes GAB2 from many GWAS-identified loci whose function remains unclear.

The GAB2 pathway also intersects with APOE4 biology. APOE4 is known to impair PI3K/AKT signaling; reduced GAB2 activity may compound this impairment, explaining why the protective effect of high-GAB2 variants is particularly pronounced in APOE ε4 carriers⁵⁵ the protective effect of high-GAB2 variants is particularly pronounced in APOE ε4 carriers
the two pathways converge on the same tau phosphorylation axis.

The Evidence

Reiman et al. (2007) conducted a genome-wide SNP survey across neuropathologically verified AD cases and controls⁶⁶ Reiman et al. (2007) conducted a genome-wide SNP survey across neuropathologically verified AD cases and controls
n=1,411 across three cohorts, published in Neuron, identifying a GAB2 haplotype strongly associated with AD protection in APOE ε4 carriers (lead variant rs2373115, OR=4.06). The rs7101429 variant was among the haplotype-tagging SNPs and has since become the most widely replicated individual marker in this region.

Schjeide et al. (2009) attempted replication in more than 4,000 DNA samples from approximately 1,300 AD families⁷⁷ Schjeide et al. (2009) attempted replication in more than 4,000 DNA samples from approximately 1,300 AD families
published in Archives of Neurology and found that rs7101429 was the only GAB2 variant to yield consistent significant association (P=0.002), with minor allele (G) carriers showing approximately 30% reduced AD risk. Crucially, the protective direction matched the original GWA study.

Zou et al. (2013) performed a meta-analysis across four North American case-control series (2,316 LOAD cases, 2,538 controls), combined with all previously published data⁸⁸ Zou et al. (2013) performed a meta-analysis across four North American case-control series (2,316 LOAD cases, 2,538 controls), combined with all previously published data
up to 22,253 total samples. After pooling, protective GAB2 variants showed odds ratios of 0.82–0.88 (all p<0.04). Critically, they linked the genetic protection to biology: higher GAB2 mRNA levels in postmortem brain tissue correlated with fewer neurofibrillary tangles (r=−0.34, p=0.0006) and fewer senile plaques (r=−0.32, p=0.001) in 249 individuals, directly connecting the expression quantitative trait to pathological endpoints.

Liang et al. (2011) extended the evidence using FDG-PET brain imaging in 158 cognitively normal APOE ε4 carriers⁹⁹ Liang et al. (2011) extended the evidence using FDG-PET brain imaging in 158 cognitively normal APOE ε4 carriers
published in NeuroImage, showing that carriers of the protective GAB2 haplotype maintained higher glucose metabolism in bilateral temporal, parietal, and occipital regions — precisely the areas that deteriorate earliest in Alzheimer's disease. This metabolic preservation was detectable decades before any clinical symptoms.

Replication is mixed: Chapuis et al. (2008) found only a marginal trend across 3,155 French participants¹⁰¹⁰ Chapuis et al. (2008) found only a marginal trend across 3,155 French participants
OR=1.3 for the GG genotype in APOE4 carriers, p=0.09; Neurobiology of Disease, and a Japanese cohort showed no association at all. A Chinese case-control study (Wang et al. 2011, n=310) identified an independent protective signal, though the effect direction question in that population remains complex. The overall evidence places GAB2 rs7101429 as a moderate-evidence risk modifier¹¹¹¹ moderate-evidence risk modifier
consistent direction in larger meta-analyses, but not uniformly replicated across all populations.

Practical Implications

Unlike pharmacogenomic variants with direct drug-dosing implications, rs7101429 informs risk stratification rather than a specific therapeutic target. For carriers of one or two A alleles (the majority of people), the actionable implication is heightened awareness of strategies that specifically support the PI3K/AKT-tau phosphorylation axis — particularly interventions with evidence for reducing tau pathology, not just generic dementia prevention.

Since the GAB2/PI3K/AKT axis regulates tau phosphorylation directly, interventions that modulate this pathway deserve priority. Omega-3 fatty acids (DHA in particular) activate PI3K/AKT signaling in neurons and have been shown to reduce tau phosphorylation in animal models. Curcumin and berberine are established GSK-3β inhibitors studied in the context of tau pathology. Monitoring for early cognitive changes — particularly episodic memory and executive function — enables earlier intervention if needed.

Interactions

The most clinically significant interaction is with APOE ε4 status (determined by rs429358 and rs7412). Reiman et al.'s original finding was specifically in APOE ε4 carriers¹²¹² Reiman et al.'s original finding was specifically in APOE ε4 carriers
where the GAB2 haplotype modified risk substantially, and Ikram et al.'s meta-analysis (PMID 19118819) showed pooled ORs specifically in ε4 carriers. Individuals who carry both the A risk genotype at rs7101429 and APOE ε4 may face compounded risk through the convergence of impaired PI3K/AKT signaling (GAB2 pathway) and APOE4's independent effects on lipid transport, amyloid clearance, and neuroinflammation.

rs2373115 (the original lead GAB2 variant from the Reiman 2007 GWAS) and rs4945261 (a second independently associated GAB2 variant) are in partial linkage disequilibrium with rs7101429 and define the extended protective haplotype. Users who are heterozygous at rs7101429 may benefit from inspecting their rs2373115 result, as the two-SNP haplotype carries more information than either alone.